Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study

Autor: Josep M. Llibre, Judith A. Aberg, Sharon Walmsley, Juan Velez, Carlos Zala, Brenda Crabtree Ramírez, Bronagh Shepherd, Rimi Shah, Andrew Clark, Allan R. Tenorio, Amy Pierce, Fangfang Du, Bo Li, Marcia Wang, Shiven Chabria, Michael Warwick-Sanders

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

IntroductionFostemsavir is a gp120-directed attachment inhibitor approved for heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1. We provide detailed week 240 safety results from the BRIGHTE study and evaluate the impact of imm

Externí odkaz: https://doaj.org/article/1a438b85ab0540d88cd5bbc43749a960

Phase III / IV , Randomized, Fifty‐Two –Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Autor: David M. Roth, Susan W Burriss, Michelle Miller, J. Groark, Kathleen Maksimowicz-McKinnon, Luiz Sergio Guedes Barbosa, Amy Pierce, Ellen M. Ginzler, Mittermayer Barreto Santiago, Beulah Ji, Jennifer A Gilbride, Saira Z Sheikh, Richard Furie, Amit Saxena, Jim C. Oates, Damon Bass, David D'Cruz

Publikováno v: Arthritis & Rheumatology. 74:112-123

Objective Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in Phase 2 and 3 belimumab trials was not reflective of the racial distribution observed in the lupus population. This study assessed efficacy and safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50c9fae2800aa2420a308a9eff97554a
https://doi.org/10.1002/art.41900

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

Autor: Margaret Gartland, Pedro Cahn, Edwin DeJesus, Ricardo Sobhie Diaz, Robert Grossberg, Michael Kozal, Princy Kumar, Jean-Michel Molina, Fernando Mendo Urbina, Marcia Wang, Fangfang Du, Shiven Chabria, Andrew Clark, Louise Garside, Mark Krystal, Frank Mannino, Amy Pierce, Peter Ackerman, Max Lataillade

Publikováno v: Antimicrobial agents and chemotherapy. 66(6)

In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1 RNA40 copies/mL was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca164c81f83ac3fbfea14ba8e642b0a9
https://pubmed.ncbi.nlm.nih.gov/35502922

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

Autor: Michael, Kozal, Judith, Aberg, Gilles, Pialoux, Pedro, Cahn, Melanie, Thompson, Jean-Michel, Molina, Beatriz, Grinsztejn, Ricardo, Diaz, Antonella, Castagna, Princy, Kumar, Gulam, Latiff, Edwin, DeJesus, Mark, Gummel, Margaret, Gartland, Amy, Pierce, Peter, Ackerman, Cyril, Llamoso, Max, Lataillade, A, Wurcel

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2020, 382 (13), pp.1232-1243. ⟨10.1056/nejmoa1902493⟩

International audience; Background: Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5a254ab693219f5158d10a1eab75d5
https://doi.org/10.1056/nejmoa1902493

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

Autor: Max Lataillade, Marcia Wang, Debbie Hagins, Miranda Murray, Andrew Clark, William J. Towner, Amy Pierce, Sarah-Jane Anderson, Robert M. Grossberg, Peter Ackerman, David Cella, Cyril Llamoso

Publikováno v: The Patient

Introduction Heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) have limited viable antiretroviral regimens available because of multidrug resistance and safety concerns. The first-in-class HIV-1 attachment inhibitor fostemsavir demo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faaec0abaecb02cad2d4a6cbdf955e63
https://pubmed.ncbi.nlm.nih.gov/34180035